Please note: The information displayed on this page might be outdated.
GenSight Biologics: Gene therapy: retinal & CNS degenerative pathologies and mitochondrial disease. Lead, GS010, Ph 3 for Leber Hereditary Optic Neuropathy (LHON). REVERSE Ph 3 topline data announced Apr 2018, RESCUE Ph 3 72-week data reported April 2019. Third Ph 3, REFLECT, exp 2020. Filing for MAA exp Q1 2020 in EU and Q4 2020 in US. Pipeline concomitant program, GS030: optogenetic combo drug + enhancing goggle device: non-syndromic retinitis pigmentosa. Optogenetic program and targeted disease immediately transferable to dry AMD. Platform combines mono-genetic therapy-based approach w core technology platform and proprietary Mitochondrial Targeting Sequence.
Based in...
Clinical Stage
Phase III
Disease Space
Europe, Public
Market Cap
100MM - 500MM
Therapeutic Modalities
Gene Therapy
74, rue du Faubourg Saint-Antoine
Paris, 75012

Company Participants at GenSight KOL Event June

  • Bernard Gilly, Co-Founder & CEO

Top 10 Holders of Gensight Biologics SA

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Sycomore Asset Management SA 1.85 605,911 2.33 Funds 12/31/19
Fidelity Management & Research Co. LLC 0.78 225,059 0.86 Funds 7/31/20
Amilton Asset Management SA 0.43 140,000 0.54 Funds 12/31/19
Gestys SA 0.22 65,000 0.25 Funds 6/26/20
La Financière de L’Europe SAS 0.17 50,000 0.19 Funds 7/31/20
Meeschaert Asset Management SA 0.04 11,000 0.04 Funds 8/31/20
Chaussier Gestion SA 0.03 7,500 0.03 Funds 6/26/20
DWS Investment GmbH 0.02 5,607 0.02 Funds 6/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.